KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) EBT: 2009-2024

Historic EBT for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to -$1.3 billion.

  • Teva Pharmaceutical Industries' EBT rose 299.38% to $646.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $896.0 million, marking a year-over-year increase of 148.22%. This contributed to the annual value of -$1.3 billion for FY2024, which is 105.77% down from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported EBT of -$1.3 billion as of FY2024, which was down 105.77% from -$624.0 million recorded in FY2023.
  • Teva Pharmaceutical Industries' EBT's 5-year high stood at $658.0 million during FY2021, with a 5-year trough of -$4.4 billion in FY2020.
  • For the 3-year period, Teva Pharmaceutical Industries' EBT averaged around -$1.7 billion, with its median value being -$1.3 billion (2024).
  • Per our database at Business Quant, Teva Pharmaceutical Industries' EBT skyrocketed by 114.93% in 2021 and then crashed by 580.70% in 2022.
  • Yearly analysis of 5 years shows Teva Pharmaceutical Industries' EBT stood at -$4.4 billion in 2020, then spiked by 114.93% to $658.0 million in 2021, then slumped by 580.70% to -$3.2 billion in 2022, then soared by 80.27% to -$624.0 million in 2023, then slumped by 105.77% to -$1.3 billion in 2024.